Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 10/20 | 0.40 |
| ▸ | JAK1 | P23458 | 10/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497229 | 0.91 | MEN1 (0.43) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL849908 | 0.91 | USP2 (0.47) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL23803010 | 0.90 | HPGD (0.43) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL851117 | 0.87 | USP2 (0.42) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL13064565 | 0.85 | HPGD (0.43) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL20669219 | 0.82 | USP2 (0.43) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL28604412 | 0.80 | VNN1 (0.46) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL28587335 | 0.80 | VNN1 (0.46) | USP2SMN1; SMN2CTSKJAK2JAK1 | |
| SCHEMBL2378427 | 0.80 | USP2 (0.42) | USP2SMN1; SMN2CTSKMEN1ALDH1A1 | |
| SCHEMBL2377946 | 0.80 | VNN1 (0.46) | USP2SMN1; SMN2CTSKJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121872968-A | Synthesis method of 1-Boc-3-aminopyrrolidine-3-formic acid | 上海毕臣生化科技有限公司 | 2026-04-17 | — | — | CN | disclosed |
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | PLEXXIKON INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3229805-B1 | SPIROCYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| US-11332496-B2 | Stapled and stitched polypeptides and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
| WO-2021113625-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2020017569-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日本ケミファ株式会社 | 2020-01-23 | — | — | WO | disclosed |
| US-20190202862-A1 | STAPLED AND STITCHED POLYPEPTIDES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2019-07-04 | — | — | US | disclosed |
| US-10221186-B2 | Spirocyclic heterocyclic compounds useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170334924-A1 | Spirocyclic Heterocyclic Compounds Useful As HIV Integrase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334924-A1 | Spirocyclic Heterocyclic Compounds Useful As HIV Integrase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20160024153-A1 | STAPLED AND STITCHED POLYPEPTIDES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024153-A1 | STAPLED AND STITCHED POLYPEPTIDES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2014159969-A1 | STAPLED AND STITCHED POLYPEPTIDES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-02 | — | — | WO | disclosed |
| US-7202246-B2 | Spiro-rifamycin derivatives targeting RNA polymerase | CUMBRE PHARMACEUTICALS INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050277633-A1 | E.g., rifamycin S derivatives such as 2',2'-Dimethyl-3,4-piperazinorifamycin S and Spiro[N-methyl-piperidine-3,4-piperazinorifamycin S; treating bacterial infections, especially those caused by rifamycin-resistant bacteria | CUMBRE INC. (US) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | USP2 4645/4885SMN1; SMN2 1090/4885CTSK 2006/4885 |
| US-20050277633-A1 | E.g., rifamycin S derivatives such as 2',2'-Dimethyl-3,4-piperazinorifamycin S and Spiro[N-methyl-piperidine-3,4-piperazinorifamycin S; treating bacterial infections, especially those caused by rifamycin-resistant bacteria | RIF1, MAPRE1, MAPRE2 | USP2 4847/4885SMN1; SMN2 4541/4885CTSK 3168/4885 |
| US-20160024153-A1 | STAPLED AND STITCHED POLYPEPTIDES AND USES THEREOF | VIP, NGLY1, F13A1 | USP2 3470/4885SMN1; SMN2 1803/4885CTSK 1838/4885 |
| US-20170334924-A1 | Spirocyclic Heterocyclic Compounds Useful As HIV Integrase Inhibitors | CCNY, CDKN1A, RPIA | USP2 4818/4885SMN1; SMN2 3943/4885CTSK 3684/4885 |
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ADORA1, ADORA2A | USP2 4811/4885SMN1; SMN2 1647/4885CTSK 2470/4885 |
| US-20190202862-A1 | STAPLED AND STITCHED POLYPEPTIDES AND USES THEREOF | VIP, NGLY1, IAPP | USP2 3099/4885SMN1; SMN2 1638/4885CTSK 1759/4885 |
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1H | USP2 3277/4885SMN1; SMN2 2838/4885CTSK 3884/4885 |
| US-10221186-B2 | Spirocyclic heterocyclic compounds useful as HIV integrase inhibitors | CCNY, CDKN1A, RPIA | USP2 4818/4885SMN1; SMN2 3943/4885CTSK 3684/4885 |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | USP2 2866/4885SMN1; SMN2 3420/4885CTSK 823/4885 |
| US-11332496-B2 | Stapled and stitched polypeptides and uses thereof | VIP, NGLY1, IAPP | USP2 3099/4885SMN1; SMN2 1638/4885CTSK 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.